Agency: Guidance Favors Market Innovation Over Federal Scrutiny. New artificial intelligence-enabled health wearable devices and clinical decision support software will not face U.S. Food and Drug Administration regulatory scrutiny, providing the technology meets certain criteria, such as being low-risk, the agency said this week.
First seen on govinfosecurity.com
Jump to article: www.govinfosecurity.com/fda-takes-hands-off-approach-to-ai-devices-software-a-30465
